Opinion|Videos|June 27, 2024
BOND-003: Clinical Implications for HR BCG-Unresponsive NMIBC Treatment
Author(s)Gary Steinberg, MD, FACS
Gary D. Steinberg, MD explains the implications of the BOND-003 results for clinical practice in treating non-muscle-invasive bladder cancer (NMIBC), highlighting the potential benefits of novel immunotherapeutic options like cretostimogene grenadenorepvec as a bladder-sparing therapy for BCG-unresponsive high-risk NMIBC, and discusses how this treatment could fit into the NMIBC treatment landscape if approved.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What could the results from BOND-003 mean for clinical practice in the treatment of patients with non-muscle-invasive bladder cancer (NMIBC)?
- What type of patient could benefit from novel immunotherapeutic options (bladder sparing therapy) for BCG-unresponsive high-risk non-muscle-invasive bladder cancer?
- If approved, how does cretostimogene fit into the treatment landscape for patients with NMBIC?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5
